| Johnson & Johnson (JNJ) | |||
|---|---|---|---|
| 226.835 0.675 (0.3%) | 04-22 09:41 | ||
| Open: | 225.99 | Pre. Close: | 226.16 |
| High: | 227.46001 | Low: | 225.99 |
| Volume: | 402,773 | Market Cap: | 546,649(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: | |
| Target: | Six months: 278.70 One year: 288.74 |
| Support: | Support1: 224.70 Support2: 186.95 |
| Resistance: | Resistance1: 238.61 Resistance2: 247.21 |
| Pivot: | 238.29 |
| Moving Averages: | MA(5): 232.85 MA(20): 238.59 MA(100): 226.39 MA(250): 191.55 |
| MACD: | MACD(12,26): -2.08 Signal(12,26,9): -0.57 |
| %K %D: | %K(14,3): 9.05 %D(3): 14.76 |
| RSI: | RSI(14): 28.64 |
| 52-Week: | High: 251.71 Low: 146.12 Change(%): 47.4 |
| Average Vol(K): | 3-Month: 8397 10-Days: 8353 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 232.368 - 234.597 | 234.597 - 235.946 |
| Low: | 219.952 - 222.873 | 222.873 - 224.639 |
| Close: | 222.829 - 227.559 | 227.559 - 230.419 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ JNJ ] has closed below the lower bollinger band by 12.0%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 22.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey. |
| Stock chart |
|---|
![]() |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: New York Stock Exchange | |
| Sector: Healthcare | |
| Industry: Drug Manufacturers - General | |
| Shares Out. (M) | 2410.00 |
| Shares Float (M) | 2410.00 |
| % Held by Insiders | 0.06 |
| % Held by Institutions | 75.82 |
| Shares Short (K) | 22270 |
| Shares Short Prior Month (K) | 25090 |
| Stock Financials | |
|---|---|
| EPS | 11.030 |
| Book Value (p.s.) | 33.870 |
| Profit Margin | 21.83 |
| Operating Margin | 26.72 |
| Return on Assets (ttm) | |
| Return on Equity (ttm) | |
| Qtrly Rev. Growth | 9.9 |
| Gross Profit (p.s.) | 27.187 |
| Sales Per Share | 39.983 |
| EBITDA (p.s.) | 14.149 |
| Qtrly Earnings Growth | -52.90 |
| Operating Cash Flow (M) | |
| Levered Free Cash Flow (M) | |
| Stock Valuation | |
|---|---|
| PE Ratio | 20.50 |
| PEG Ratio | 3.05 |
| Price to Book value | 6.68 |
| Price to Sales | 5.66 |
| Price to Cash Flow | |
| Stock Dividends | |
|---|---|
| Dividend | 1.300 |
| Dividend Yield | 0.01 |
| Dividend Growth | |